Hepatopulmonary syndrome and liver transplantation: Who, when, and where?
Rajasekhar Tanikella, Michael B. Fallon – 7 March 2013
Hepatopulmonary syndrome and liver transplantation: Who, when, and where?
Rajasekhar Tanikella, Michael B. Fallon – 7 March 2013
The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus
Piero Amodio, Chantal Bemeur, Roger Butterworth, Juan Cordoba, Akinobu Kato, Sara Montagnese, Misael Uribe, Hendrik Vilstrup, Marsha Y. Morgan – 7 March 2013 – Nitrogen metabolism plays a major role in the development of hepatic encephalopathy (HE) in patients with cirrhosis. Modulation of this relationship is key to the management of HE, but is not the only nutritional issue that needs to be addressed. The assessment of nutritional status in patients with cirrhosis is problematic.
Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice
Xin‐An Wang, Ran Zhang, Dingsheng Jiang, Wei Deng, Shumin Zhang, Shan Deng, Jinfeng Zhong, Tao Wang, Li‐Hua Zhu, Li Yang, Shufen Hong, Sen Guo, Ke Chen, Xiao‐Fei Zhang, Zhigang She, Yingjie Chen, Qinglin Yang, Xiao‐Dong Zhang, Hongliang Li – 7 March 2013 – Obesity is a calorie‐excessive state associated with high risk of diabetes, atherosclerosis, and certain types of tumors. Obesity may induce inflammation and insulin resistance (IR).
MicroRNA‐216a/217‐induced epithelial‐mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer
Hongping Xia, London Lucien P.J. Ooi, Kam M. Hui – 7 March 2013 – Tumor recurrence and metastases are the major obstacles to improving the prognosis of patients with hepatocellular carcinoma (HCC). To identify novel risk factors associated with HCC recurrence and metastases, we have established a panel of recurrence‐associated microRNAs (miRNAs) by comparing miRNA expression in recurrent and nonrecurrent human HCC tissue samples using microarrays (recurrence is defined as recurrent disease occurring within a 2‐year time point of the original treatment).
Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy
Beverley Kok, Matthew R. Foxton, Christopher Clough, Debbie L. Shawcross – 7 March 2013
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome
Greg C. G. Hugenholtz, Jelle Adelmeijer, Joost C. M. Meijers, Robert J. Porte, R. Todd Stravitz, Ton Lisman – 6 March 2013 – Emerging evidence supports the concept of a rebalanced hemostatic state in liver disease as a result of a commensurate decline in prohemostatic and antihemostatic drivers. In the present study, we assessed levels and functionality of the platelet‐adhesive protein von Willebrand factor (VWF) and its cleaving protease ADAMTS13 in the plasma of patients with acute liver injury and acute liver failure (ALI/ALF).
Left renal vein ligation during liver transplantation in a recipient with a single kidney
Tércio Genzini, Alisson Paulino Trevizol, Eduardo Tomohissa Yamashita, Huda Maria Noujaim, Regina Gomes Santos, Marilia Tavares Campos Oliveira Gaboardi, Leonardo Toledo Mota, Juan Raphael Brañez Pereira, Leonardo Ogawa Oliveira, Marcelo Perosa – 6 March 2013
Preparing for the inevitable: The death of a living liver donor
Charles Miller, Martin L. Smith, Masato Fujiki, Teresa Diago Uso, Cristiano Quintini – 6 March 2013 – Living donor liver transplantation (LDLT) is associated with a low but finite and well‐documented risk of donor morbidity and mortality, so organizations and individuals involved in this activity must accept the fact that a donor death is a question of when and not if.
High incidence of treatment‐induced and vaccine‐escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients
Karine Lacombe, Anders Boyd, Fabien Lavocat, Christian Pichoud, Joel Gozlan, Patrick Miailhes, Caroline Lascoux‐Combe, Guy Vernet, Pierre‐Marie Girard, Fabien Zoulim – 6 March 2013 – Anti–hepatitis B virus (HBV) nucleos(t)ides analogs (NA) exert selective pressures on polymerase (pol) and surface (S) genes, inducing treatment resistance and increasing the risk of vaccine escape mutants. The rate of emergence for these mutations is largely unknown in patients coinfected with human immunodeficiency virus (HIV) and HBV undergoing dual‐active therapy.